GlassScriptPhysician profile
Vanessa L Dickey
NPI 1497742472
$1,123.22
in general payments reported to CMS, 2019-2025
14 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.26 · 2021: $15.38 · 2022: $58.74 · 2023: $338 · 2024: $309 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.84 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $505.02 | 2022-2025 | Calquence |
| Abbvie INC. | $134.22 | 2020-2025 | Venclexta |
| Array Biopharma INC | $84.55 | 2024-2025 | Braftovi, Tukysa, Ibrance |
| Pfizer INC. | $78.14 | 2023-2024 | |
| Glaxosmithkline, LLC. | $67.46 | 2022-2024 | Zejula, Jemperli |
| Celgene Corporation | $46.66 | 2022-2025 | Reblozyl |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Accord Healthcare, INC. | $30.16 | 2025 | |
| Genentech USA, INC. | $29.03 | 2023 | Venclexta |
| Merck Sharp & Dohme LLC | $27.06 | 2025 | Welireg, Keytruda |
| Spectrum Pharmaceuticals INC. | $21.83 | 2024 | Rolvedon |
| Janssen Biotech, INC. | $21.30 | 2023 | Erleada |
| E.R. Squibb & Sons, L.L.C. | $20.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Dickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.